Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 3

1(20.0%)

5Total

N/A(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05845710Not ApplicableCompleted

Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)

Role: collaborator

NCT04201132Not ApplicableActive Not Recruiting

Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System

Role: collaborator

NCT01568164Not ApplicableCompleted

Safety and Efficacy Study of the BioVentrix PliCath HF System

Role: collaborator

NCT01568138Not ApplicableCompleted

Prospective Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy

Role: collaborator

NCT02266810Phase 3Completed

Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus

Role: collaborator

All 5 trials loaded